Connect your AI

Omnicell OMCL 2029

2029 at other companies

Cardinal HealthCAH

——

ICU MedicalICUI

——

HaemoneticsHAE

——

SolventumSOLV

——

Medline, Inc. MDLN

——

GHC

Graham HoldingsGHC

——

Other financials

Income statement

Revenue$309.9M+14.9%

Gross profit$140.4M+26.5%

Operating income$16.9M+245%

Net income$11.4M+262%

EPS (diluted)$0.25+267%

Balance sheet

Cash & equivalents$291.0M-29.8%

Total debt$34.3M-23.1%

Total equity$1.3B0.0%

Total assets$2.0B-6.8%

Cash flow

Operating cash flow$54.5M+110%

CapEx$12.4M+11.3%

Free cash flow$42.1M+185%

Valuation

Market cap$1.8B-7.2%

Enterprise value$1.54B-0.4%

P/E116.4×—

P/S1.5×-0.2×

Profitability

Gross margin43.5%+0.4pp

Operating margin2.7%+1.8pp

Net margin1.7%+1.1pp

FCF margin9.3%-1.7pp

Returns & leverage

Return on equity1.6%+1.1pp

Debt / equity0×0.0×

Current ratio1.5×+0.1×

Where this comes from

Reported directly by Omnicell in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree.

The official record: Omnicell’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omnicell's 2029.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Omnicell's 2029?: Omnicell (OMCL) reported 2029 of $13.95M in Q1 2026.
How has Omnicell's 2029 changed year-over-year?: Omnicell's 2029 decreased by 7.9% year-over-year, from $15.15M to $13.95M.